Evidence map›Paper›PMID 33911328›Full record

ArticleAustralian prescriber2021

Elimination of hepatitis C in Australia by 2030: a decade and counting.

Gregory J Dore

Registry-linked trialAbstract readEditorial
In one paragraph

Article in Australian prescriber, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07560046 (Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07560046 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations

TypeinterventionalSponsorDuke UniversityRan2026 to 2030Enrolled1,280ConditionsHIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)ArmsCepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2, Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Developing a primary care-initiated hepatitis C treatment pathway in Scotland: a qualitative study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gregory J DoreInfectious diseases physician, St Vincent's Hospital, Sydney.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

direct-acting antiviral drugshepatitis Chepatocellular carcinomaliver disease

Identifiers

PMID33911328
PMCPMC8075743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.